PFE Talzenna combo shows strong efficacy in wider prostate cancer use

Pfizer PFE reported positive top-line results from a late-stage study evaluating Talzenna (talazoparib), an oral PARP inhibitor, in combination with Xtandi (enzalutamide), an ARP inhibitor. The regimen was studied in patients with HRR gene-mutated metastatic castration-sensitive prostate cancer (mCSPC), also known as metastatic hormone-sensitive prostate cancer. Talzenna was initially approved in the United States, the EU and several other...